115 related articles for article (PubMed ID: 28913538)
21. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
22. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
23. Proteasome inhibition leads to altered signaling in the proteome of cisplatin-resistant human ovarian carcinoma cell line.
Duraj J; Pastorek M; Vitkovska J; Cholujova D; Gronesova P; Hunakova L; Sedlak J
Neoplasma; 2013; 60(6):627-34. PubMed ID: 23906297
[TBL] [Abstract][Full Text] [Related]
24. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
[TBL] [Abstract][Full Text] [Related]
25. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.
Sullivan EJ; Kurtoglu M; Brenneman R; Liu H; Lampidis TJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):417-27. PubMed ID: 24352250
[TBL] [Abstract][Full Text] [Related]
26. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
Song J; Shih IeM; Salani R; Chan DW; Zhang Z
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
[TBL] [Abstract][Full Text] [Related]
27. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
28. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer.
Yahata H; Kobayashi H; Kamura T; Amada S; Hirakawa T; Kohno K; Kuwano M; Nakano H
J Cancer Res Clin Oncol; 2002 Nov; 128(11):621-6. PubMed ID: 12458343
[TBL] [Abstract][Full Text] [Related]
29. [Relationship between the Akt-regulated direct p53 mitochondrial translocation and the resistance to cisplatin of ovarian cancer cells].
Zhou Y; Wang SY; Yang XK; Wang HM
Zhonghua Zhong Liu Za Zhi; 2011 Feb; 33(2):97-100. PubMed ID: 21575475
[TBL] [Abstract][Full Text] [Related]
30. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
32. Anion exchange chromatography for the determination of 5-methyl-2'-deoxycytidine: application to cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines.
Iglesias T; Espina M; Montes-Bayón M; Sierra LM; Blanco-González E
Anal Bioanal Chem; 2015 Mar; 407(9):2423-31. PubMed ID: 25142048
[TBL] [Abstract][Full Text] [Related]
33. Nuclear and mitochondrial distribution of organoamidoplatinum(II) lesions in cisplatin-sensitive and -resistant adenocarcinoma cells.
Talarico T; Cullinane CM; Gray PJ; Webster LK; Deacon GB; Phillips DR
Anticancer Drug Des; 2001; 16(2-3):135-41. PubMed ID: 11962511
[TBL] [Abstract][Full Text] [Related]
34. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin.
Yu R; Jin H; Jin C; Huang X; Lin J; Teng Y
Cell Biochem Funct; 2018 Mar; 36(2):80-87. PubMed ID: 29372560
[TBL] [Abstract][Full Text] [Related]
36. Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer.
Chappell NP; Teng PN; Hood BL; Wang G; Darcy KM; Hamilton CA; Maxwell GL; Conrads TP
J Proteome Res; 2012 Sep; 11(9):4605-14. PubMed ID: 22900918
[TBL] [Abstract][Full Text] [Related]
37. Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells.
Britten RA; Hardy C; Vlahou A; Gregory B; Giri PS; Drake R
Oncol Rep; 2005 Nov; 14(5):1323-30. PubMed ID: 16211304
[TBL] [Abstract][Full Text] [Related]
38. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
39. cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines.
Ormerod MG; O'Neill C; Robertson D; Kelland LR; Harrap KR
Cancer Chemother Pharmacol; 1996; 37(5):463-71. PubMed ID: 8599870
[TBL] [Abstract][Full Text] [Related]
40. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
